Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Inclusion Criteria:

1. ECOG PS 0 or 1

2. HLA-A*02:01 positive

3. PRAME positive tumor

4. Relapsed from, refractory to, or intolerant of standard therapies; or, incombination with standard therapies

5. If applicable, must agree to use highly effective contraception

Exclusion Criteria:

1. Symptomatic or untreated central nervous system metastasis

2. Recent bowel obstruction

3. Ongoing ascites or effusion requiring recent drainages

4. Significant immune-mediated adverse event with prior immunotherapy (Participants incheckpoint inhibitor combination treatment)

5. Inadequate washout from prior anticancer therapy

6. Significant ongoing toxicity from prior anticancer treatment

7. Out-of-range laboratory values

8. Clinically significant lung, heart, or autoimmune disease

9. Ongoing requirement for immunosuppressive treatment

10. Prior solid organ or bone marrow transplant

11. Active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiencyvirus (HIV) infection

12. Significant secondary malignancy

13. Hypersensitivity to study drug or excipients

14. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of studyintervention

15. Pregnant or lactating participants

16. Any other contraindication for applicable combination partner based on localprescribing information